Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

urticaria

9 posts
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Novartis Pharma AG Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs…
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Novartis Pharma AG Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs…
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
NNovartis
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Read More

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

  • 2026-06-09
Novartis Pharma AG Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible…
NNovartis
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Read More

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

  • 2026-06-09
Novartis Pharma AG Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible…
NNovartis
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
Read More

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

  • 2026-06-03
Novartis Pharma AG Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 &…
NNovartis
Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 
Read More

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria 

  • 2026-04-27
Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
NNovartis
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Read More

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

  • 2026-02-23
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…
NNovartis
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Read More

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

  • 2026-02-18
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1…
Switzerland
www.europesays.com